RADFORD, Va., July 19 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (proposed Nasdaq National Market Symbol: NRPH) announced today the filing with the Securities and Exchange Commission on July 16, 2004, of an amended registration statement on Form S-1 for the proposed initial public offering of its common stock. All of the 4,200,000 shares proposed to be offered will be offered by the company. In addition, the company will grant to the underwriters the right to purchase up to an additional 630,000 shares to cover over-allotments. The public offering price is expected to be between $10.00 and $14.00 per share.
New River Pharmaceuticals is a specialty pharmaceutical company focused on developing novel pharmaceuticals that are safer and improved versions of widely-prescribed drugs, including amphetamines and opioids.
WR Hambrecht + Co is acting as the lead underwriter of the offering. First Albany Capital, Wells Fargo Securities, LLC and Punk, Ziegel & Company are acting as co-managers. The offering will be made through WR Hambrecht + Co's OpenIPO(R) auction-based process.
The public offering will be made only by means of a prospectus, which may be obtained by going to WR Hambrecht's web site http://www.wrhambrecht.com/, by calling 800-673-6476 or by writing to WR Hambrecht + Co, P.O. Box 677, Berwyn, PA 19312.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
Contact: The Ruth Group Stephanie Carrington 646-536-7017 scarrington@theruthgroup.com
New River Pharmaceuticals Inc.CONTACT: Stephanie Carrington of The Ruth Group, +1-646-536-7017,scarrington@theruthgroup.com , for New River Pharmaceuticals
Web site: http://www.wrhambrecht.com/
